ES2535401T3 - Composiciones para el tratamiento de enfermedades neoplásicas - Google Patents

Composiciones para el tratamiento de enfermedades neoplásicas

Info

Publication number
ES2535401T3
ES2535401T3 ES08788414.4T ES08788414T ES2535401T3 ES 2535401 T3 ES2535401 T3 ES 2535401T3 ES 08788414 T ES08788414 T ES 08788414T ES 2535401 T3 ES2535401 T3 ES 2535401T3
Authority
ES
Spain
Prior art keywords
docetaxel
ritonavir
weight
pvp
taxane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08788414.4T
Other languages
English (en)
Spanish (es)
Inventor
Jacob Hendrik Beijnen
Johannes Henricus Matthias Schellens
Johannes Moes
Bastiaan Nuijen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STICHTING NL KANKER INST
Netherlands Cancer Institute
SLOTERVAART PARTICIPATIES BV
Original Assignee
STICHTING NL KANKER INST
Netherlands Cancer Institute
SLOTERVAART PARTICIPATIES BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STICHTING NL KANKER INST, Netherlands Cancer Institute, SLOTERVAART PARTICIPATIES BV filed Critical STICHTING NL KANKER INST
Priority claimed from PCT/GB2008/002854 external-priority patent/WO2009027644A2/en
Application granted granted Critical
Publication of ES2535401T3 publication Critical patent/ES2535401T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES08788414.4T 2007-08-24 2008-08-22 Composiciones para el tratamiento de enfermedades neoplásicas Active ES2535401T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95776407P 2007-08-24 2007-08-24
GB0716591 2007-08-24
US957764P 2007-08-24
GB0716591A GB0716591D0 (en) 2007-08-24 2007-08-24 Composition
PCT/GB2008/002854 WO2009027644A2 (en) 2007-08-24 2008-08-22 Composition

Publications (1)

Publication Number Publication Date
ES2535401T3 true ES2535401T3 (es) 2015-05-11

Family

ID=38599259

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08788414.4T Active ES2535401T3 (es) 2007-08-24 2008-08-22 Composiciones para el tratamiento de enfermedades neoplásicas

Country Status (5)

Country Link
JP (1) JP5404625B2 (enExample)
CN (1) CN101854919B (enExample)
ES (1) ES2535401T3 (enExample)
GB (1) GB0716591D0 (enExample)
RU (1) RU2488384C2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9867801B2 (en) 2014-03-31 2018-01-16 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN105106420A (zh) * 2015-07-30 2015-12-02 马衍福 一种抗肿瘤疾病中药制剂
EP3595633B1 (en) 2017-03-15 2023-07-05 DFB Soria, LLC Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
JP7317804B2 (ja) 2017-09-07 2023-07-31 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド ドセタキセル結合体の医薬組成物及び調製方法
PE20220250A1 (es) 2018-12-21 2022-02-16 Modra Pharmaceuticals B V Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
PE20220129A1 (es) * 2018-12-21 2022-01-27 Modra Pharmaceuticals B V Tratamiento de combinacion para tumores solidos usando docetaxel y un inhibidor de cyp3a

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1180020B2 (en) * 1999-05-27 2009-06-24 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
AU2003256157A1 (en) * 2002-08-05 2004-02-23 Dsm Ip Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
KR100508518B1 (ko) * 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9867801B2 (en) 2014-03-31 2018-01-16 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same

Also Published As

Publication number Publication date
GB0716591D0 (en) 2007-10-03
RU2010110658A (ru) 2011-09-27
CN101854919B (zh) 2012-02-15
RU2488384C2 (ru) 2013-07-27
CN101854919A (zh) 2010-10-06
JP2010536837A (ja) 2010-12-02
BRPI0816144A2 (pt) 2015-02-18
JP5404625B2 (ja) 2014-02-05

Similar Documents

Publication Publication Date Title
ES2535401T3 (es) Composiciones para el tratamiento de enfermedades neoplásicas
AU2022256110A1 (en) Hsp90 inhibitor oral formulations and related methods
CN105338977A (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
ES2734081T3 (es) Apilimod para el uso en el tratamiento de melanoma
KR20090067210A (ko) 페닐알킬 카바메이트 조성물
JP2021523169A (ja) ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法
BR112020023204A2 (pt) composições que compreendem compostos de bisfluoroalquil-1,4-benzodiazepinona e métodos de uso dos mesmos
ES3027420T3 (en) Pharmaceutical composition for preventing or treating nonalcoholic steatohepatitis
MX2010012937A (es) Combinacion farmaceutica.
RU2712187C2 (ru) Фармацевтические композиции и их применение
ES3042094T3 (en) Vaginal delivery systems containing selective estrogen receptor modulator (serm) and uses thereof
ES2398640T3 (es) Formulaciones de análogos 14-epi de la vitamina D
RU2334517C2 (ru) Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство
US20120101057A1 (en) Combined therapy of colorectal carcinoma
JP2557303B2 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
ES2339265T3 (es) Uso de acetil l-carnitina en combinacion con propionil l-carnitina y sildenafil para el tratamiento de la difuncion erectil.
Cao et al. Effect of food components and dosing times on the oral pharmacokinetics of nifedipine in rats
RU2575819C2 (ru) Новые составы 14-эпи-аналогов витамина d
RU2575792C2 (ru) Составы 14-эпи-аналогов витамина d
CA3240171A1 (en) A formulation for an effective oral administration of ciclopirox with no adversal gasterointestinal toxicity
WO2009056256A1 (en) Use of megestrol acetate having improved solubility for the treatment of cancer cachexia
BR112020024346A2 (pt) métodos para aumentar a exposição de sepiapterina no plasma
NZ737544B2 (en) Micronized compound a, compositions and use thereof
JP2006518355A (ja) インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法
HK40007250A (en) Use of neurokinin-1 antagonists to treat a variety of pruritic conditions